INBX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
-100.0%
1.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
-100.0%
1.3M
Operating Expenses
32.1M
+4.0%
30.9M
+0.0%
30.9M
-8.5%
33.8M
+17.9%
28.7M
R&D
23.9M
-5.2%
25.2M
-0.5%
25.3M
-11.2%
28.5M
+28.1%
22.3M
SG&A
8.3M
+44.5%
5.7M
+2.4%
5.6M
+5.6%
5.3M
-17.8%
6.4M
Operating Income
-32149000
-4.0%
-30927000
-0.0%
-30923000
+8.5%
-33812000
-23.5%
-27389000
EBITDA
-31626000
-4.1%
-30390000
-0.1%
-30359000
+8.6%
-33229000
-24.3%
-26728000
Net Income
-36650000
-9.6%
-33441000
-1.8%
-32834000
+6.9%
-35256000
-23.0%
-28654000
EPS (Basic)
$-2.34
-8.8%
$-2.15
-1.9%
$-2.11
+7.5%
$-2.28
-23.2%
$-1.85
EPS (Diluted)
$-2.34
-8.8%
$-2.15
-1.9%
$-2.11
+7.5%
$-2.28
-23.2%
$-1.85
Shares (Diluted)
15.7M
+0.5%
15.6M
+0.3%
15.5M
+0.4%
15.5M
+0.1%
15.5M
Inhibrx Biosciences (INBX) โ€” Financials